Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
T cell killing by tolerogenic dendritic cells protects mice from allergy
Ulrike Luckey, Marcus Maurer, Talkea Schmidt, Nadine Lorenz, Beate Seebach, Martin Metz, Kerstin Steinbrink
Ulrike Luckey, Marcus Maurer, Talkea Schmidt, Nadine Lorenz, Beate Seebach, Martin Metz, Kerstin Steinbrink
View: Text | PDF
Research Article Immunology

T cell killing by tolerogenic dendritic cells protects mice from allergy

  • Text
  • PDF
Abstract

It is well established that allergy development can be prevented by repeated low-dose exposure to contact allergens. Exactly which immune mechanisms are responsible for this so-called low zone tolerance (LZT) is not clear, although CD8+ suppressor T cells are known to have a role. Here, we show that TNF released by tolerogenic CD11+CD8+ DCs located in skin-draining lymph nodes is required and sufficient for development of tolerance to contact allergens in mice. DC-derived TNF protected mice from contact allergy by inducing apoptosis in allergen-specific effector CD8+ T cells via TNF receptor 2 but did not contribute to the generation and function of the regulatory T cells associated with LZT. The TNF-mediated killing mechanism was induced in an allergen-specific manner. Activation of tolerogenic DCs by LZT CD8+ suppressor T cells and enhanced TNF receptor 2 expression on contact allergen–specific CD8+ effector T cells were required for LZT. Our findings may explain how tolerance protects from allergic diseases, which could allow for the development of new strategies for allergy prevention.

Authors

Ulrike Luckey, Marcus Maurer, Talkea Schmidt, Nadine Lorenz, Beate Seebach, Martin Metz, Kerstin Steinbrink

×

Figure 6

LZT is associated with increased TNF/p75-induced apoptosis in CHS effector CD8+ T cells.

Options: View larger image (or click on image) Download as PowerPoint
LZT is associated with increased TNF/p75-induced apoptosis in CHS effect...
(A–D) Apoptosis in lymph node cells obtained 24 hours after challenge from tolerized and sensitized Tnf–/– and corresponding WT mice (A and B) and from p75–/– and corresponding WT mice (C and D). CD8+ T cell apoptosis was detected by flow cytometry (annexin V staining, pooled cells obtained from 5–6 animals). 1 of 4 experiments with similar results (A and C) and pooled data of 4 experiments (B and D) are shown. (E and F) Percentages of apoptotic Thy1.2+ CD8+ T cells as assessed by flow cytometry (annexin V+/CD8+) in lymph node cells obtained after challenge with TNCB from TNCB-tolerized or mock-tolerized Thy1.1+ mice that were then reconstituted with T cells isolated from TNCB-sensitized Thy1.2+ mice (E) or in lymph node cells obtained after challenge with DNFB from TNCB-tolerized or mock-tolerized Thy1.1+ mice that had been reconstituted with T cells isolated from DNFB-sensitized Thy1.2+ mice (F). For analyses, gate was set on Thy1.2+ T cells (derived from the sensitized donor mice). 1 of 3 independent experiments with similar results is shown. 5 per group per experiment were used. Data are shown as mean ± SD. *P < 0.05; **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts